In addition to their well-established cardiorenal benefits, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are increasingly preferred as effective treatments for obesity, have not demonstrated consistent evidence of disproportionate lean mass loss or reductions in muscle strength in body composition analyses [28]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.